

TR-14035

Catalog No: tcsc1812

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:

232271-19-1

Formula:

 $\mathsf{C}_{\mathbf{24}}\mathsf{H}_{\mathbf{21}}\mathsf{CI}_{\mathbf{2}}\mathsf{NO}_{\mathbf{5}}$

Pathway:

Cytoskeleton

Target:

Integrin

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 41 mg/mL (86.44 mM)

Observed Molecular Weight:

474.33

Product Description

TR-14035 is a a dual alpha4beta7(IC50=7 nM)/alpha4beta1 (IC50=87 nM) integrin antagonist .

Copyright 2021 Taiclone Biotech Corp.




IC50 Value: alpha(4)beta(7)/alpha(4)beta(1)=7/87 nM [1]

Target: integrin

TR14035 blocked the binding of human alpha(4)beta(7) to an (125)I-MAdCAM-Ig fusion protein with IC(50) values of 0.75 nM. TR14035 blocked binding of human alpha(4)beta(7)-expressing RPMI-8866 cells or murine mesenteric lymph node lymphocytes to MAdCAM-Ig with IC(50) values of 0.1 microM [2].

TR14035 blocked adhesion to HEVs [ED(50) of 0.01-0.1 mpk i.v.].

TR-14035 was taken up by rat and human hepatocytes by an apparently single saturable mechanism with K(m) of 6.7 and 2.1 microM, respectively, and taurocholate and digoxin reduced this uptake [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.